News · Equities · MarketWatch · Tue, Sep 22, 2026 4:00 PM
This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for th
Image from the source feed · MarketWatch
OpenBook briefing: This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month. What it means for
OpenBook market desk: Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
Why this matters for multi-asset traders
The headline theme is "This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month". We reframe the story for readers tracking equities, FX majors and crypto liquidity - without copying the original wording.
Watch related price action on OpenBook movers and treat this note as information, not investment advice.
Based on reporting from MarketWatch. Read the original.